← SynDRA
PF-06952229
SynDRA canonical compound SYN0040442 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | TGFBR1 |
|---|
| Mechanism of action | antineoplastic agent |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- antineoplastic agent
- TGFBR1 INHIBITOR
Cross-references
Synonyms
- PF06952229
- SCHEMBL16879380
- BDBM280355
- US10030004, Compound 22
- NSC826119
- NSC-826119
- HY-136244
- CS-0120989
- ClC=1C=CC(=C(C1)C1=NC=C(C(=C1)NC1=CC=NC=C1C(=O)NC(CO)CO)C(C)C)F
- Synthesis of 4-[[2-(5-chloro-2-fluoro-phenyl)-5-isopropyl-4-pyridyl]amino]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]pyridine-3-carboxamide
- Pf 06952229
- 1KKS7U3X86
- UNII-1KKS7U3X86
- PF 06952229 [WHO-DD]
- C23H24ClFN4O3
- orb1708884
- SCHEMBL30556480
- SCHEMBL31061472
- GLXC-23516
- BXC33355
- EX-A5069
- AKOS040734464
- MS-28403
- G17439
Look up PF-06952229 in the interactive SynDRA portal →